RE:RE:articleYou have to understand the signification of a "narrow indication". Every oncologic drug on the market have a limited label. Meaning they are limited to a specific (or limited) population.
If the FDA approves a label that includes 60 % of the initial targeted population by the sponsor, will you call it a double-narrowed of a narrower indication ? My point is...the word "narrowed" is irrelevant here. You get an approval for a specific population. Bottom line.
At worst, TST will get an approval for a population of several thousands of patients (on-label). Which is not bad at all compared to a lot of other oncologic drugs label.
M80